Rational Use of Antimicrobials

Chapter 18


Rational Use of Antimicrobials



Antibiotic use in the intensive care unit (ICU) has been impacted by two major trends. First, although the number of antibiotics available for use in the ICU setting rose dramatically through the 1980s, the number of new antimicrobial agents approved by the Food and Drug Administration (FDA) has decreased by 80% since the 1990s. Second, many pathogens infecting ICU patients have become increasingly resistant to both older and newer antimicrobial agents, often the result of starting or continuing antibiotics that are inappropriate for the clinical situation. As a result, there has been an effective decline in the number of antibiotics available for use in the ICU, which some have labeled as a return to the preantibiotic era. This emphasizes the importance of a rational approach to both empirical and directed use of antibiotics in the ICU.



Empirical Antimicrobial Therapy


Rational initiation of empirical antibiotic therapy requires an understanding of the complexities involved in the diagnosis of infection in the ICU setting. First, ICU patients with underlying infection often may not exhibit the usual signs and symptoms of infection like fever, or leukocytosis. Likewise, even when these classic signs are present (Chapter 13), they can be problematic because none of them alone, or even in combination, is highly predictive of an underlying infection.



Fever and Leukocytosis


Fever is defined as an elevated core body temperature albeit with no consensus as to the specific threshold temperature that qualifies as a fever. For example, the Centers for Disease Control and Prevention (CDC) uses  > 100° F for a fever in its case definition of influenza and > 101° F ( > 38.0° C) for the purposes of surveillance for health care–associated infections (HAIs) (nosocomial infections). Fever is caused by the release of cytokines (so-called endogenous pyrogens, e.g., IL1) in response to injury, inflammation, antigenic challenge, or infection. Thus, fever itself cannot reliably distinguish infectious from noninfectious causes. Despite its seemingly common occurrence, few prospective data exist on the frequency and causes of fever specifically in ICU patients. A small prospective study in adult ICU patients published in 1999 showed that fever occurred in 70% of ICU admissions but was associated with infection in only 53% of cases, confirming that fever is not a specific marker for infection. Furthermore, fever has been found to be present in only half the cases of sepsis and postoperative infections, indicating that it is also not a sensitive marker for infection in these populations.


In non-ICU studies, many hospitalized patients with fever but no clinical evidence for infection received antibiotics, suggesting that much of the antibiotic use in non-ICU patients that is initiated for fevers alone is unnecessary and can be eliminated without jeopardizing patient care. By inference, starting antibiotics for fever alone in ICU patients is inappropriate (with the exception of patients with neutropenia [see Chapter 24]), and the presence of fever should instead stimulate a systematic search for its cause (see Chapters 13 and 14).


Like fever, leukocytosis (elevated white blood cell [WBC] count, specifically WBC > 15,000 cells/μL) also has a low specificity. Although such a degree of leukocytosis is associated with an increased risk of bacterial infection, almost half of such patients have no identifiable infection.



Systemic Inflammatory Response Syndrome (SIRS), Sepsis, and Septic Shock


The systemic inflammatory response syndrome (SIRS) is defined as the simultaneous presence of two or more physiologic signs that can result from systemic inflammation: (1) fever (or hypothermia), (2) tachycardia, (3) tachypnea, and (4) a neutrophilic leukocytosis. SIRS can arise from infectious or noninfectious causes. Sepsis has been defined as SIRS with clinical evidence (or high suspicion) of infection. Severe sepsis refers to the clinical situation of sepsis with evidence of (otherwise unexplained) inadequate end organ perfusion. Septic shock is severe sepsis with clinically significant hypotension (see Chapter 10). Even though infection is common in patients with severe sepsis (present in ~90% of patients in one large prospective epidemiologic study), bloodstream infection (bacteremia or fungemia) was documented in only about one quarter of this group of patients overall.


Despite the above-mentioned limitations of using fever, leukocytosis, and SIRS/sepsis as markers of infections, these signs are still clinically important and their presence should always prompt a thorough search for their cause (see Chapters 10, 13, and 14).


An additional complexity of diagnosing infection in ICU patients is that even objective clinical data, such as microbiologic cultures, can often be confusing. For example, a positive culture of sputum or a tracheal aspirate for a pathogenic organism does not necessarily prove the presence of a health care–associated pneumonia or even tracheobronchitis. Likewise, a negative culture—for example, a tracheal aspirate sent the day after the start of new antimicrobials—does not confirm the absence of infection. Finally, some culture results may be uninterpretable because of an ill-considered approach to the diagnostic evaluation, such as relying exclusively on blood cultures obtained from existing central venous catheters without the benefit of cultures drawn from a peripheral site. This can complicate the interpretation of cultures growing common skin contaminants such as coagulase-negative Staphylococcus species (see Chapter 14).


A final consideration when selecting an appropriate empirical antibiotic regimen is an appreciation of the epidemiology of common health care–associated infections within one’s own ICU and hospital. Rates of health care–associated infections among ICU admissions range from 3% to 31% and can vary between community and university hospitals as well as between different types of ICUs within the same hospital. Likewise, the prevalence of specific pathogens and their antimicrobial resistance patterns can vary considerably among different hospitals, ICU types, and even over time within the same ICU. Understanding one’s local epidemiology is crucial for selecting a regimen that provides adequate antimicrobial coverage for the most likely infecting pathogens while also minimizing the risk of promoting antimicrobial resistance with agents that have too broad a spectrum of coverage.



Antibiotic Stewardship in the ICU


Antimicrobial stewardship is a rational, systematic approach to the use of antimicrobial agents that involves selecting an appropriate drug and optimizing its dose and duration in order to cure an infection, while minimizing toxicity and conditions for selection of resistant bacterial strains. The most common errors in antibiotic use in the ICU are both in the incorrect initial choice of empirical agents as well as in the failure to narrow antimicrobial coverage and limit antibiotic duration once the results of cultures and diagnostic studies become available.


Since the early 2000s, there has been a significant rise in the prevalence of multidrug-resistant organisms, especially among infections found in the ICU. More than half of Staphylococcus aureus isolates in ICUs are methicillin resistant, and resistance of certain gram-negative organisms to third-generation cephalosporins, fluoroquinolones, and carbapenems can be as high as 20% to 30%. Failure to select an empirical antimicrobial regimen for critically ill patients that covers such pathogens when present can have serious implications, as inadequate initial antibiotic therapy is associated with worse clinical outcomes. Choice of specific empirical agents should thus be guided by antibiotic resistance patterns in one’s own community and hospital.


By the same token, limiting the spectrum and duration of antimicrobials when appropriate is equally, if not more, important. Often overlooked or minimized, the complications of antimicrobial use are important to consider at both the individual and community levels. Toxicities, such as renal failure, Clostridium difficile infection, drug fever, and serious allergic reactions, are associated with increased morbidity and mortality and lead to further diagnostic studies as well as additional hospitalization days and increased costs of care. Furthermore, ICU patients given broad-spectrum antibiotics are predisposed to colonization and eventual infection with resistant organisms such as methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococcus (VREC), vancomycin-intermediate S. aureus, extended-spectrum beta-lactamase–producing (ESBL+) Enterobacteriaceae, carbapenemase-producing Enterobacteriaceae, and multidrug-resistant Acinetobacter baumannii. Exposure to broad-spectrum antibiotics is also a known risk factor for the development of invasive fungal infections. Infections with any of these resistant organisms or fungi lead to poor clinical outcomes for the patients as well as negative institutional and economic outcomes.

< div class='tao-gold-member'>

Jul 7, 2016 | Posted by in CRITICAL CARE | Comments Off on Rational Use of Antimicrobials

Full access? Get Clinical Tree

Get Clinical Tree app for offline access